Trial Profile
A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Oral AKT Inhibitor GSK2110183 Administered in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Afuresertib (Primary) ; Bortezomib; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms PKB115125
- Sponsors GlaxoSmithKline; Novartis
- 11 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 May 2015 to 1 Aug 2015.
- 13 Jul 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 May 2015 to 1 Aug 2015.